Amakem Nv

Amakem Raises 18m in a Series a Round to Advance its Ophthalmology Drug Development Programs

Older News

DIEPENBEEK, Belgium, September 6, 2011 - 'Localized Drug Action' platform generates novel kinase inhibitors for eye conditions including glaucoma Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy